Melissa Sherman

Dr. Melissa Sherman is the CEO of MOBILion Systems Inc., a life science tools company accelerating biotherapeutic drug development and multiomic biomarker discovery. She is a passionate business builder with public and private company leadership experience in multiple industries including fashion apparel, consumer products, and FDA-regulated surgical materials. Dr. Sherman joined MOBILion from IP Group, an early-stage technology investment firm, where she managed portfolio development from federal laboratory technology and was responsible for deal origination, due diligence, and transaction execution. Prior to IP Group, Dr. Sherman spent 15 years as an executive in the regenerative medicine industry with W.L. Gore & Associates, Kensey Nash, and Aimago, developing and executing a strategy that led to the acquisition of Aimago by Novadaq/Stryker and of Kensey Nash by DSM. Dr. Sherman started her career at DuPont, transitioning from scientist to six sigma black belt, holding multiple marketing, business development, and senior leadership positions in the fashion, textile, nonwoven, and consumer fibers industries.

Dr. Sherman received her Ph.D. in Polymer Chemistry from the University of Akron and B.S. in Chemistry from the University of Wisconsin - Eau Claire.